ストックスクリーナーアプリを入手
246.43
0.64%
1.49
前日終値:
$244.94
開ける：
$243.95
24時間の取引高:
331.08K
Relative Volume:
0.31
時価総額：
$35.97B
収益：
$5.26B
当期純損益:
$1.44B
株価収益率:
25.22
EPS:
9.7713
ネットキャッシュフロー:
$1.76B
1週間 パフォーマンス:
-2.60%
1か月 パフォーマンス:
-1.69%
6か月 パフォーマンス:
-2.83%
1年 パフォーマンス:
+3.89%
1日の値動き範囲:
$243.07
$247.21
1週間の範囲:
$241.66
$249.92
52週間の値動き範囲:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
RMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
246.41 | 35.75B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
580.78 | 202.94B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
197.29 | 55.73B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.55 | 39.28B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
42.65 | 32.78B | 0 | 0 | 0 | 0.00 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-09-02 | アップグレード | CLSA | Hold → Outperform |
| 2025-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
Thrivent Financial for Lutherans Acquires 5,212 Shares of ResMed Inc. $RMD - MarketBeat
Texas Permanent School Fund Corp Sells 5,560 Shares of ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock beat revenue estimatesPortfolio Performance Report & Intraday High Probability Alerts - ulpravda.ru
Technical Analysis: Will ResMed Inc. stock gain from strong economyTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is ResMed Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Real-Time Volume Analysis - DonanımHaber
Will ResMed Inc. stock deliver better than expected guidanceJuly 2025 Movers & Long Hold Capital Preservation Tips - DonanımHaber
Resmed Inc Officer Plans Sale of Common Stock - MSN
Will ResMed Inc. stock attract more institutional investorsMarket Volume Report & Real-Time Volume Triggers - Улправда
Will ResMed Inc. stock benefit from automationQuarterly Trade Review & Growth-Oriented Investment Plans - DonanımHaber
Why ResMed Inc. stock is a value investor pickJuly 2025 Short Interest & Smart Money Movement Tracker - Улправда
ResMed Inc. $RMD Shares Acquired by Addenda Capital Inc. - MarketBeat
Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape - Kalkine Media
Is ResMed Inc. stock in correction or buying zoneJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Stifel Maintains ResMed (RMD) Hold Recommendation - Nasdaq
Will ResMed Inc. (RME) stock outperform Dow Jones2025 Momentum Check & Community Trade Idea Sharing Platform - Улправда
Stifel Nicolaus Adjusts ResMed Price Target to $260 From $270, Maintains Hold Rating - marketscreener.com
Stifel Lowers Price Target for ResMed (RMD) to $260, Maintains H - GuruFocus
How ResMed Inc. stock performs in easing cyclesJuly 2025 WrapUp & AI Driven Price Predictions - Улправда
Aug Volume: Can ResMed Inc. stock double in next 5 yearsGold Moves & Reliable Intraday Trade Alerts - Улправда
ResMed stock price target lowered to $260 by Stifel on Philips return concerns - Investing.com UK
ResMed (RMD): Revisiting Valuation After Recent Share Price Pullback - Yahoo Finance
ResMed (NYSE:RMD) Downgraded to "Hold" Rating by Baird R W - MarketBeat
4,600 Shares in ResMed Inc. $RMD Purchased by Sanders Morris Harris LLC - MarketBeat
ResMed Inc (NYSE:RMD) s&p 500 index Digital Health Footprint - Kalkine Media
Tandem upgraded, Zimmer, ResMed downgraded as Baird previews MedTech in 2026 - MSN
Shorts Report: Will ResMed Inc stock benefit from automationWeekly Profit Analysis & Breakout Confirmation Trade Signals - moha.gov.vn
ResMed (RMD) Downgraded by Baird, Price Target Lowered to $275 | - GuruFocus
Baird Downgrades ResMed to Neutral From Outperform, Adjusts Price Target to $275 From $300 - marketscreener.com
Baird downgrades ResMed stock rating to Neutral on slowing growth By Investing.com - Investing.com Australia
Baird downgrades ResMed stock rating to Neutral on slowing growth - Investing.com
ResMed (RMD): Evaluating the Stock’s Valuation After FDA Clearance for Its AI-Powered Smart Comfort CPAP Feature - Sahm
Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors - WebWire
Is ResMed stock underperforming the S&P 500? - MSN
ResMed Inc. $RMD Shares Acquired by Neuberger Berman Group LLC - MarketBeat
MASTERINVEST Kapitalanlage GmbH Takes $3.02 Million Position in ResMed Inc. $RMD - MarketBeat
FORA Capital LLC Purchases New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc announces proposed sale of securities by director - MSN
How FDA-Cleared AI Smart Comfort Personalization At ResMed (RMD) Has Changed Its Investment Story - Sahm
What analysts say about ResMed Inc stockEarnings Call Summaries & Breakthrough Profit Margins - earlytimes.in
Loss Report: Will ResMed Inc stock benefit from automationJuly 2025 Recap & Reliable Breakout Stock Forecasts - moha.gov.vn
ResMed stock price target raised to $345 from $335 at UBS - Investing.com
Ilex Capital Partners UK LLP Takes $39.31 Million Position in ResMed Inc. $RMD - MarketBeat
Bayesian Capital Management LP Buys Shares of 17,316 ResMed Inc. $RMD - MarketBeat
AdvaMed Names Resmed CEO Mick Farrell as Next Board Chair - Medical Product Outsourcing
ResMed Inc. $RMD Shares Sold by Frontier Capital Management Co. LLC - MarketBeat
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
FDA clearances: Medtronic, Insulet, Resmed - Modern Healthcare News
Cerity Partners LLC Acquires 29,205 Shares of ResMed Inc. $RMD - MarketBeat
CW Advisors LLC Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed (NYSE:RMD) Shares Gap UpHere's What Happened - MarketBeat
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
3.24%
大文字化:
|
ボリューム (24 時間):